Abstract:As COVID-19 ravages healthcare systems worldwide, cases of infection among patients with systemic lupus erythematosus (SLE) are increasingly reported. While there had been 2 reports on incident hospitalized cases from the US and France,1, 2 there have been no reports of SLE patients with COVID-19 infection from the Asia Pacific region. The Asia Pacific Lupus Collaboration (APLC) patient cohort comprises 3375 patients from 25 centers in Australia, China, Hong Kong, Indonesia Japan, Korea, Malaysia, New Zealand, Philippines, Singapore, Sri Lanka, Taiwan, Thailand.3 On 3 June, principal investigators of APLC centers were asked to respond to a brief email questionnaire regarding current or historical COVID-19 cases in their cohorts. Patients and the public were not involved in the conduct of this research. Table 1 describes the number of COVID-19 patients, number of SLE patients and the prevalence of hydroxychloroquine use. In total, only 3 cases of COVID-19 were reported. Here, we briefly describe their clinical course. Patient 1 was a 58-year-old Japanese woman with stable SLE, maintained on prednisolone monotherapy (5 mg daily) without hydroxychloroquine. Her daughter was diagnosed with COVID-19 infection and the patient was found to be positive for SARS-CoV-2 on screening. Although she was asymptomatic, her clinical course was complicated by severe thrombocytopenia (nadir 5 × 109/L) which required intravenous immunoglobulin and prednisolone 20 mg daily. The thrombocytopenia was attributed to SLE flare as its severity was assessed to be out of proportion to her asymptomatic COVID-19 infection. In addition, hypocomplementemia was observed. Platelet count eventually improved and she was discharged. Patient 2 was a 32-year-old Filipino woman with active lupus nephritis who was treated with hydroxychloroquine, mycophenolate mofetil and prednisolone 30 mg daily. She resided 5 hours away from her lupus center and had a history of poor treatment adherence. During the pandemic, only phone consultations were performed, during one of which she informed her rheumatologist that she had been initiated on hemodialysis at a local hospital for deteriorating renal function. Subsequently, her rheumatologist was informed that she had passed away from COVID-19 pneumonia at the provincial hospital. Details surrounding her COVID-19 infection were not accessible. Patient 3 was a 29-year-old Filipino woman with SLE (on hydroxychloroquine, azathioprine and low-dose prednisolone), hypertensive heart disease and chronic kidney disease who presented with bilateral COVID-19 pneumonia and peripheral edema. Concurrently, she was found to have active lupus nephritis which required increase in prednisolone to 50 mg daily. She was discharged when pneumonia and lupus nephritis improved. In summary, we report three cases of COVID-19 infection in SLE patients from the Asia Pacific, of which one was fatal. Notably, all three patients had active SLE which required escalation of treatment just before, or during treatment for COVID-19 infection, in contrast to reports from France.2 Importantly, patient 2 could not directly access her rheumatologist during the pandemic and only phone consultations were used. Further research on the impact of reduced care access and the utility of alternative care models, such as teleconsultation, is needed for patients with SLE. While the incidence of COVID-19 in SLE is unknown, 16 (4%) of the 450 patients in the Colombia Lupus Cohort developed symptomatic COVID-19 infection.1 Based on a report censored on 15 April in Hong Kong, none of the 1016 COVID-19 cases had a history of SLE.4 In this report, we describe only 3 cases identified among our 3375 SLE patients. Although we did not systematically capture infection rates in a protocolized manner, the low number of COVID-19 infections, at ~ 0.1% of the APLC cohort, does not suggest a major burden of COVID-19 among SLE patients. Possible reasons accounting for this included the low background prevalence of COVID-19 in the region compared with other parts of the world at the time of the report and increased measures taken by SLE patients to avoid infections. We eagerly await data from other SLE cohorts. The authors declare no competing interests. AL, RKR, EM and CJC contributed to the conception or design of the work. All authors contributed to the acquisition, analysis and interpretation of data. CJC, RKR and AL drafted the work. All coauthors revised it critically for important intellectual content. Final approval of the version published was obtained from all authors. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Principal Investigators of individual centers obtained valid written informed consent in accordance with local authority regarding ethical conduct of human research, which conformed to the provisions of the Declaration of Helsinki. In addition, Monash University ethics approval has been obtained to store the pooled database, perform analyses and subsequently publish the findings.

Systemic lupus erythematosus is associated with increased risk of mortality and acute kidney injury in patients with COVID-19 hospitalization: Insights from a National Inpatient Sample analysis

Causes of Death in Hospitalized Patients with Systemic Lupus Erythematosus: a 10-Year Multicenter Nationwide Chinese Cohort

COVID‐19 Infection in Patients with Systemic Lupus Erythematosus: Data from the Asia Pacific Lupus Collaboration

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients

Peripheral Blood Mononuclear Cells and Serum Cytokines in Patients with Lupus Nephritis after COVID-19

Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China

Risk of systemic lupus erythematosus flare after COVID-19 hospitalization: A matched cohort study

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Analysis of United States Nationwide Inpatient Sample Database 2016–2019

Creatinine clearance rate predicts prognosis of patients with systemic lupus erythematosus: a large retrospective cohort study

Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus

Systemic lupus erythematosus manifestation following COVID-19: a case report

Clinical Outcomes of Acute Myocardial Infarction Hospitalizations With Systemic Lupus Erythematosus: An Analysis of Nationwide Readmissions Database

Clinical features and predictions of in-hospital mortality in 91 patients with systemic lupus erythematosus

Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort

Mortality and prognostic factors among inpatients with systemic lupus erythematosus in China: A 20-year retrospective study

Risk factors for hospitalization in Mexican patients with systemic lupus erythematosus

Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects

Trends and disparities in cardiovascular deaths in systemic lupus erythematosus: A population-based retrospective study in the United States from 1999 to 2020

Risk factors for in-hospital mortality among patients hospitalized with COVID-19 and end-stage kidney disease

Clinical Characteristics and Prognoses of Patients with Systemic Lupus Erythematosus Hospitalized for Pulmonary Infections